Literature DB >> 19950093

Left ventricular thrombus mimicking primary cardiac tumor in a patient with primary antiphospholipid syndrome and recurrent systemic embolism.

Tomás F Cianciulli1, María C Saccheri, Jorge A Lax, Roberto O Neme, Juan F Alvarez Sevillano, María E Maiori, Sebastian Fandino Lound, Coloma E Parisi, Horacio A Prezioso, Luis A Vidal.   

Abstract

Primary antiphospholipid syndrome (APS) is a well-defined entity characterized by spontaneous and recurrent abortion, thrombocytopenia and recurrent vascular thromboses (arterial and venous). Left ventricular thrombus mimicking primary cardiac tumor with recurrent systemic embolism has not been previously reported. In this report we describe a 39 year-old man admitted to hospital presenting with left hemiparesis and a peripheral embolism. He had no history of thrombotic events. Transthoracic echocardiography showed a large, polypoid and mobile mass (4.0 x 1.2 cm) attached to the apex of the left ventricle, highly suggestive of primary cardiac tumor. The patient subsequently underwent open heart surgery. The histological examination showed an older thrombus and a fresh thrombus. Post-operative laboratory tests showed lupus anticoagulant activity, confirming the primary APS diagnosis. The patient initiated treatment with oral anticoagulation (INR levels between 2 and 3) and was discharged 29 days after surgery. At ten month follow-up, he was symptom-free with long-term anticoagulation therapy. No evidence of intracardiac mass recurrence on two-dimensional echocardiography was seen. Intracardiac thrombus has been rarely reported as a complication of primary APS. Left ventricular mass mimicking primary cardiac tumor with recurrent systemic embolism has not been previously reported. Pre-operative investigations could not distinguish such a thrombus from a cardiac tumor and the diagnosis was made post-operatively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19950093

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  7 in total

1.  Surgical treatment of cardiac tumors: a 5-year experience from a single cardiac center.

Authors:  Liang Yin; Dengke He; Hua Shen; Xinyu Ling; Wei Li; Qian Xue; Zhinong Wang
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  [Decompensated heart failure as a result of a systemic disease].

Authors:  B Greiner; K Remde; H-M Lorenz; R Max
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-04-11       Impact factor: 0.840

Review 3.  Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin.

Authors:  George Markousis-Mavrogenis; Petros P Sfikakis; Sophie I Mavrogeni; Maria G Tektonidou
Journal:  Clin Rheumatol       Date:  2020-11-16       Impact factor: 2.980

4.  Mortality and embolic potential of cardiac tumors.

Authors:  Ricardo Ribeiro Dias; Fábio Fernandes; Félix José Alvarez Ramires; Charles Mady; Cícero Piva Albuquerque; Fábio Biscegli Jatene
Journal:  Arq Bras Cardiol       Date:  2014-07-15       Impact factor: 2.000

5.  Metastatic leiomyosarcoma presenting as a lung mass with left atrial extension: case report and anesthetic management.

Authors:  Yinyin Qu; Qing Zheng; Cheng Ni; Zhongqi Cui; Xiangyang Guo
Journal:  Ther Clin Risk Manag       Date:  2018-01-19       Impact factor: 2.423

Review 6.  Cardiac Magnetic Resonance in Rheumatology to Detect Cardiac Involvement Since Early and Pre-clinical Stages of the Autoimmune Diseases: A Narrative Review.

Authors:  Lilia M Sierra-Galan; Mona Bhatia; Angel Leovigildo Alberto-Delgado; Javier Madrazo-Shiordia; Carlos Salcido; Bernardo Santoyo; Eduardo Martinez; Maria Elena Soto
Journal:  Front Cardiovasc Med       Date:  2022-07-13

Review 7.  Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature.

Authors:  Jariya Waisayarat; Sirithep Plumworasawat; Soamarat Vilaiyuk; Nongnuch Sirachainan
Journal:  Vasc Health Risk Manag       Date:  2019-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.